Differentiation therapies in human cancers

Abstract

Yue Hongyun, Zhang Baihong. Differentiation therapies in human cancers[J]. Journal of International Oncology, 2024, 51(2): 109-113.

Figures/Tables1

细胞可塑	作用机制	药物类型	临床试验
诱导分化	表观遗传剂	EZH2抑制剂，HDAC抑制剂	临床前研究^{[ 10 ⇓ - 12 ]}
	自噬诱导剂	ULK1抑制剂	临床前研究^{[ 13 ]}
	干性调节剂	SOX2抑制剂，Wnt抑制剂，MEK抑制剂，erastin	临床前研究^{[ 15 ⇓ - 17 ]}
启动分化	代谢调节剂	Vorasidenib	Ⅱ期^{[ 20 - 21 ]}
	转录因子调节剂	SOX10拮抗剂	临床前研究^{[ 25 ]}
	免疫细胞分化剂	抗PD-1/PD-L1抗体	临床应用^{[ 27 - 28 ]}
调控分化	染色质可塑剂	Exportin1抑制剂，LSD1抑制剂	临床前研究^{[ 33 ⇓ - 35 ]}
	血管生成抑制剂	瑞格非尼	临床应用^{[ 36 ]}
	生长信号阻断剂	ZNF117	临床前研究^{[ 38 ]}
	衰老细胞清除剂	抗PD-1/PD-L1抗体	临床应用^{[ 42 ]}

References45

[1]	Pérez-González A. Bévant K, Blanpain C. Cancer cell plasticity during tumor progression, metastasis and response to therapy[J].Nat Cancer,2023,4(8): 1063-1082. DOI:10.1038/s43018-023-00595-y.
[2]	Yuan S, Norgard RJ, Stanger BZ. Cellular plasticity in cancer[J].Cancer Discov,2019,9(7): 837-851. DOI:10.1158/2159-8290.CD-19-0015. pmid:30992279
[3]	Hanahan D. Hallmarks of cancer: new dimensions[J].Cancer Discov,2022,12(1): 31-46. DOI:10.1158/2159-8290.CD-21-1059. pmid:35022204
[4]	de Thé H. Differentiation therapy revisited[J].Nat Rev Cancer,2018,18(2): 117-127. DOI:10.1038/nrc.2017.103. pmid:29192213
[5]	Barker N, Ridgway RA, van Es JH, et al. Crypt stem cells as the cells-of-origin of intestinal cancer[J].Nature,2009,457(7229): 608-611. DOI:10.1038/nature07602.
[6]	Belote RL, Le D, Maynard A, et al. Human melanocyte development and melanoma dedifferentiation at single-cell resolution[J].Nat Cell Biol,2021,23(9): 1035-1047. DOI:10.1038/s41556-021-00740-8. pmid:34475532
[7]	Kozono S, Lin YM, Seo HS, et al. Arsenic targets Pin1 and coope-rates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells[J].Nat Commun,2018,9(1): 3069. DOI:10.1038/s41467-018-05402-2.
[8]	Davalos V, Esteller M. Cancer epigenetics in clinical practice[J].CA Cancer J Clin,2023,73(4): 376-424. DOI:10.3322/caac.21765.
[9]	Feinberg AP, Levchenko A. Epigenetics as a mediator of plasticity in cancer[J].Science,2023,379(6632): eaaw3835. DOI:10.1126/science.aaw3835.
[10]	Ferrarelli LK. Exploiting an epigenetic Switch in adrenal cancer[J].Sci Signal,2023,16(794): 10. DOI:10.1126/scisignal.adj7203.
[11]	Xie J, Wang Z, Fan W, et al. Targeting cancer cell plasticity by HDAC inhibition to reverse EBV-induced dedifferentiation in nasopharyngeal carcinoma[J].Signal Transduct Target Ther,2021,6(1): 333. DOI:10.1038/s41392-021-00702-4.
[12]	Anastas JN, Zee BM, Kalin JH, et al. Re-programing chromatin with a bifunctional LSD1/HDAC inhibitor induces therapeutic differentiation in DIPG[J].Cancer Cell,2019,36(5): 528-544.e10. DOI:10.1016/j.ccell.2019.09.005. pmid:31631026
[13]	Ianniciello A, Zarou MM, Rattigan KM, et al. ULK1 inhibition promotes oxidative stress-induced differentiation and sensitizes leukemic stem cells to targeted therapy[J].Sci Transl Med,2021,13(613): eabd5016. DOI:10.1126/scitranslmed.abd5016.
[14]	Tan SH, Barker N. Stemming colorectal cancer growth and metastasis: HOXA5 forces cancer stem cells to differentiate[J].Cancer Cell,2015,28(6): 683-685. DOI:10.1016/j.ccell.2015.11.004. pmid:26678334
[15]	Zhan TZ, Ambrosi G, Wandmacher AM, et al. MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer[J].Nat Commun,2019,10(1): 2197. DOI:10.1038/s41467-019-09898-0.
[16]	Fang XG, Huang Z, Zhai K, et al. Inhibiting DNA-PK induces glioma stem cell differentiation and sensitizes glioblastoma to radiation in mice[J].Sci Transl Med,2021,13(600): eabc7275. DOI:10.1126/scitranslmed.abc7275.
[17]	Kemeny LV, Fisher DE. Targeting the (Un)differentiated State of Cancer[J].Cancer Cell,2018,33(5): 793-795. DOI:10.1016/j.ccell.2018.04.007. pmid:29763619
[18]	Malta TM, Sokolov A, Gentles AJ, et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation[J].Cell,2018,173(2): 338-354.e15. DOI:10.1016/j.cell.2018.03.034. pmid:29625051
[19]	Saha SK, Parachoniak CA, Ghanta KS, et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer[J].Nature,2014,513(7516): 110-114. DOI:10.1038/nature13441.
[20]	Molenaar RJ, Wilmink JW. IDH1/2 mutations in cancer stem cells and their implications for differentiation therapy[J].J Histochem Cytochem,2022,70(1): 83-97. DOI:10.1369/00221554211062499. pmid:34967233
[21]	Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma[J].N Engl J Med,2023,389(7): 589-601. DOI:10.1056/NEJMoa2304194.
[22]	Morris JP 4th, Yashinskie JJ, Koche R, et al. α-Ketoglutarate links p53 to cell fate during tumour suppression[J].Nature,2019,573(7775): 595-599. DOI:10.1038/s41586-019-1577-5.
[23]	Tran TQ, Hanse EA, Habowski AN, et al. α-Ketoglutarate atte-nuates Wnt signaling and drives differentiation in colorectal cancer[J].Nat Cancer,2020,1(3): 345-358. DOI:10.1038/s43018-020-0035-5.
[24]	Kaufman CK, Mosimann C, Fan ZP, et al. A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation[J].Science,2016,351(6272): aad2197. DOI:10.1126/science.aad2197.
[25]	Capparelli C, Purwin TJ, Glasheen M, et al. Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma[J].Nat Commun,2022,13(1): 1381. DOI:10.1038/s41467-022-28801-y. pmid:35296667
[26]	Henning AN, Klebanoff CA, Restifo NP. Silencing stemness in T cell differentiation[J].Science,2018,359(6372): 163-164. DOI:10.1126/science.aar5541. pmid:29326263
[27]	Gill AL, Wang PH, Lee J, et al. PD-1 blockade increases the self-renewal of stem-like CD8 T cells to compensate for their accelerated differentiation into effectors[J].Sci Immunol,2023,8(86): eadg0539. DOI:10.1126/sciimmunol.adg0539.
[28]	Castiglioni A, Yang Y, Williams K, et al. Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors[J].Nat Commun,2023,14(1): 4703. DOI:10.1038/s41467-023-40398-4. pmid:37543621
[29]	Collins SM, Alexander KA, Lundh S, et al. TOX2 coordinates with TET2 to positively regulate central memory differentiation in human CAR T cells[J].Sci Adv,2023,9(29): eadh2605. DOI:10.1126/sciadv.adh2605.
[30]	Burdziak C, Alonso-Curbelo D, Walle T, et al. Epigenetic plasticity cooperates with cell-cell interactions to direct pancreatic tumori-genesis[J].Science,2023,380(6645): eadd5327. DOI:10.1126/science.add5327.
[31]	Rüland L, Andreatta F, Massalini S, et al. Organoid models of fibrolamellar carcinoma mutations reveal hepatocyte transdifferentiation through cooperative BAP1 and PRKAR2A loss[J].Nat Commun,2023,14(1): 2377. DOI:10.1038/s41467-023-37951-6. pmid:37137901
[32]	Kim MR, Wu MJ, Zhang YS, et al. TET2 directs mammary luminal cell differentiation and endocrine response[J].Nat Commun,2020,11(1): 4642. DOI:10.1038/s41467-020-18129-w. pmid:32934200
[33]	Quintanal-Villalonga A, Durani V, Sabet A, et al. Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers[J].Sci Transl Med,2023,15(707): eadf7006. DOI:10.1126/scitranslmed.adf7006.
[34]	Duplaquet L, Li Y, Booker M, et al. KDM6A epigenetically regulates subtype plasticity in small cell lung cancer[J].Nat Cell Biol,2023,25(9): 1346-1358. DOI:10.1038/s41556-023-01210-z. pmid:37591951
[35]	Chen HY, Durmaz YT, Li Y, et al. Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1[J].Nat Commun,2022,13(1): 4998. DOI:10.1038/s41467-022-31998-7.
[36]	Deshors P, Arnauduc F, Boëlle B, et al. Impact of regorafenib on endothelial transdifferentiation of glioblastoma stem-like cells[J].Cancers (Basel),2022,14(6):1551. DOI:10.3390/cancers14061551.
[37]	Chan JM, Zaidi S, Love JR, et al. Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling[J].Science,2022,377(6611): 1180-1191. DOI:10.1126/science.abn0478.
[38]	Liu J, Wang X, Chen AT, et al. ZNF117 regulates glioblastoma stem cell differentiation towards oligodendroglial lineage[J].Nat Commun,2022,13(1): 2196. DOI:10.1038/s41467-022-29884-3.
[39]	Bala P, Rennhack JP, Aitymbayev D, et al. Aberrant cell state plasticity mediated by developmental reprogramming precedes colorectal cancer initiation[J].Sci Adv,2023,9(13): eadf0927. DOI:10.1126/sciadv.adf0927.
[40]	Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy[J].Nat Rev Drug Discov,2020,19(1): 39-56. DOI:10.1038/s41573-019-0044-1. pmid:31601994
[41]	Schmitt CA, Wang B, Demaria M. Senescence and cancer-role and therapeutic opportunities[J].Nat Rev Clin Oncol,2022,19(10): 619-636. DOI:10.1038/s41571-022-00668-4.
[42]	Wang TW, Johmura Y, Suzuki N, et al. Blocking PD-L1-PD-1 improves senescence surveillance and ageing phenotypes[J].Nature,2022,611(7935): 358-364. DOI:10.1038/s41586-022-05388-4.
[43]	张百红, 岳红云. 肿瘤休眠的周期和意义[J].现代肿瘤医学,2023,31(2): 392-394. DOI:10.3969/j.issn.1672-4992.2023.02.039.
[44]	Shen S, Vagner S, Robert C. Persistent cancer cells: the deadly survivors[J].Cell,2020,183(4): 860-874. DOI:10.1016/j.cell.2020.10.027. pmid:33186528
[45]	Lyko F. Distal memory in wound healing and cancer[J].Nat Cell Biol,2023,25(5): 631-632. DOI:10.1038/s41556-023-01132-w. pmid:37081166

Differentiation therapies in human cancers

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables1

References45

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.